Literature DB >> 20007406

Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.

Anh-Nhan Pham1, Paul E Blower, Omar Alvarado, Ranadheer Ravula, Peter W Gout, Ying Huang.   

Abstract

The x(c)(-) cystine/glutamate antiporter has been implicated in GSH-based chemoresistance because it mediates cellular uptake of cystine/cysteine for sustenance of intracellular GSH levels. Celastrol, isolated from a Chinese medicinal herb, is a novel heat shock protein 90 (Hsp90) inhibitor with potent anticancer activity against glioma in vitro and in vivo. In search of correlations between growth-inhibitory potency of celastrol in NCI-60 cell lines and microarray expression profiles of most known transporters, we found that expression of SLC7A11, the gene encoding the light chain subunit of x(c)(-), showed a strong negative correlation with celastrol activity. This novel gene-drug correlation was validated. In celastrol-resistant glioma cells that highly expressed SLC7A11, sensitivity to celastrol was consistently increased via treatment with x(c)(-) inhibitors, including glutamate, (S)-4-carboxyphenylglycine, sulfasalazine, and SLC7A11 small interfering RNA. The GSH synthesis inhibitor, buthionine sulfoximine, also increased celastrol sensitivity, whereas the GSH booster, N-acetylcysteine, suppressed its cytotoxicity. Furthermore, the glioma cell lines were dependent on x(c)(-)-mediated cystine uptake for viability, because cystine omission from the culture medium resulted in cell death and treatment with sulfasalazine depleted GSH levels and inhibited their growth. Combined treatment of glioma cells with sulfasalazine and celastrol led to chemosensitization, as suggested by increased celastrol-induced cell cycle arrest, apoptosis, and down-regulation of the Hsp90 client protein, epidermal growth factor receptor. These results indicate that the x(c)(-) transporter provides a useful target for glioma therapy. x(c)(-) inhibitors such as sulfasalazine, a Food and Drug Administration-approved drug, may be effective both as an anticancer drug and as an agent for sensitizing gliomas to celastrol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007406     DOI: 10.1124/jpet.109.162248

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

Review 1.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Authors:  Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2012-08-03       Impact factor: 8.401

2.  IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-.

Authors:  Yuzhe Yang; Douglas Yee
Journal:  Cancer Res       Date:  2014-03-31       Impact factor: 12.701

3.  Non-invasive Use of Positron Emission Tomography to Monitor Diethyl maleate and Radiation-Induced Changes in System xC- Activity in Breast Cancer.

Authors:  Milena Čolović; Hua Yang; Helen Merkens; Nadine Colpo; François Bénard; Paul Schaffer
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

4.  Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells.

Authors:  Katja Linher-Melville; Sina Haftchenary; Patrick Gunning; Gurmit Singh
Journal:  Mol Cell Biochem       Date:  2015-04-21       Impact factor: 3.396

5.  18F-5-Fluoroaminosuberic Acid as a Potential Tracer to Gauge Oxidative Stress in Breast Cancer Models.

Authors:  Hua Yang; Silvia Jenni; Milena Colovic; Helen Merkens; Carlee Poleschuk; Isabel Rodrigo; Qing Miao; Bruce F Johnson; Michael J Rishel; Vesna Sossi; Jack M Webster; François Bénard; Paul Schaffer
Journal:  J Nucl Med       Date:  2016-10-27       Impact factor: 10.057

6.  Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.

Authors:  Monika D Polewski; Rosyli F Reveron-Thornton; Gregory A Cherryholmes; Georgi K Marinov; Kaniel Cassady; Karen S Aboody
Journal:  Mol Cancer Res       Date:  2016-09-22       Impact factor: 5.852

Review 7.  Gamma-glutamyl transpeptidase: redox regulation and drug resistance.

Authors:  Marie H Hanigan
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

8.  Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.

Authors:  Carlos Gustavo Garcia; Suzana Assad Kahn; Luiz Henrique Medeiros Geraldo; Igor Romano; Ivan Domith; Deborah Christinne Lima E Silva; Fernando Dos Santos Assunção; Marcos José Ferreira; Camila Cabral Portugal; Jorge Marcondes de Souza; Luciana Ferreira Romão; Annibal Duarte Pereira Netto; Flávia Regina Souza Lima; Marcelo Cossenza
Journal:  Mol Neurobiol       Date:  2018-01-19       Impact factor: 5.590

9.  Systems biology of meridians, acupoints, and chinese herbs in disease.

Authors:  Li-Ling Lin; Ya-Hui Wang; Chi-Yu Lai; Chan-Lao Chau; Guan-Chin Su; Chun-Yi Yang; Shu-Ying Lou; Szu-Kai Chen; Kuan-Hao Hsu; Yen-Ling Lai; Wei-Ming Wu; Jian-Long Huang; Chih-Hsin Liao; Hsueh-Fen Juan
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-18       Impact factor: 2.629

10.  Transcriptional profiling of Chinese medicinal formula Si-Wu-Tang on breast cancer cells reveals phytoestrogenic activity.

Authors:  Mandy Liu; Jeffery Fan; Steven Wang; Zhijun Wang; Charles Wang; Zhong Zuo; Moses S S Chow; Leming Shi; Zhining Wen; Ying Huang
Journal:  BMC Complement Altern Med       Date:  2013-01-10       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.